Phathom Pharmaceuticals Azioni (NASDAQ: PHAT)

Ultime notizie per Phathom Pharmaceuticals (NASDAQ:PHAT) Azioni

Phathom Pharmaceuticals

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals Inc

There has been more supply, or shares for sale, than there has been demand, or shares to buy, for ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>), <a href="https://www.benzinga.com/quote/ON/news" target="_blank" rel="noopener">push</a><a href="https://www.benzinga.com/quote/ON/news">ing the price lower.</a>
There is a good chance that a new downtrend is forming. This is why our team of technical analysts has made it our Stock of the Day.
Sometimes, analysts overcomplicate technical analysis. They seem to forget that if understood and applied correctly, it is the analysis of supply and demand in a market.
If demand and supply are equal, or if there&#8217;s more demand than supply, traders and investors who wish to sell can do so without any issues. But if there is more supply than there is demand, sellers will need to offer their shares out at a discount to get the interest of those who may wish to buy.
This will force the stock into a downtrend.
Read Also: <a href="https://www.benzinga.com/markets/eurozone/25/01/42900748/us-dollar-drops-on-report-of-trump-tariff-plan-shift">US Dollar Drops on Report of Trump Tariff Plan Shift</a>
Price levels that have more demand than supply are called support levels. Downtrends pause or end when they reach support levels.
As you can see on the chart, the $61 level has been support for ON Semiconductor. Downtrends ended at this level in October 2023 and April 2024.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="556" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09151205/On-chart-1024x556.png" alt="" class="wp-image-726838" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09151205/On-chart-1024x556.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09151205/On-chart-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09151205/On-chart-768x417.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09151205/On-chart.png 1489w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Sometimes stocks rally after they reach support. This happens when some of the buyers who created the support become concerned. They are worried that other traders and investors who wish to buy will increase the prices they are willing to pay for shares.
These concerned buyers know that the sellers will go to whoever is willing to pay the highest price. As a result, they increase the prices they are willing to pay. Other concerned buyers see this and do the same thing.
This could result in a bidding war or snowball effect that pushes the price higher. This is what happened the last two times ON reached $61.
However, this support level appears to have been broken, with shares closing below it.
This could mean the people who created the support with their buy orders have left the market. They have either canceled or finished their orders.
Sellers may be forced once again to push the price lower to get the attention of buyers. This could cause a new downtrend in <a href="https://www.benzinga.com/quote/ON">ON Semiconductor</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42896114/us-2025-recession-odds-plummet-good-news-or-warning-sign">US 2025 Recession Odds Plummet: Good News Or Warning Sign?</a></li>
</ul>
Photo: Shutterstock

Technicals

Tech

Trading Ideas

Stock Of The Day: Will On Semiconductor's Meltdown Continue?

Kratos Defense &amp; Security's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NYSE">KTOS</a>) short percent of float has risen 3.0% since its last report. The company recently reported that it has 3.54 million shares sold short, which is 2.4% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.99 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Kratos Defense &amp; Security Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736453720_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Kratos Defense &amp; Security has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Kratos Defense &amp; Security's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Kratos Defense &amp; Security's peer group average for short interest as a percentage of float is 7.25%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

KTOS

Peering Into Kratos Defense & Security's Recent Short Interest

Alliant Energy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NYSE">LNT</a>) short percent of float has risen 9.49% since its last report. The company recently reported that it has 7.74 million shares sold short, which is 3.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Alliant Energy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736453715_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alliant Energy has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Alliant Energy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Alliant Energy's peer group average for short interest as a percentage of float is 2.06%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Alliant Energy?

BOK Financial's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NYSE">BOKF</a>) short percent of float has risen 25.0% since its last report. The company recently reported that it has 293 thousand shares sold short, which is 1.15% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.82 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>BOK Financial Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736453710_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for BOK Financial has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing BOK Financial's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, BOK Financial's peer group average for short interest as a percentage of float is 3.70%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

BOKF

How Is The Market Feeling About BOK Financial?

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 20 years by 6.3% on an annualized basis producing an average annual return of 14.61%. Currently, Chemed has a market capitalization of $7.97 billion. 
Buying $1000 In CHE: If an investor had bought $1000 of CHE stock 20 years ago, it would be worth $15,287.93 today based on a price of $532.02 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736453707_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Here's How Much You Would Have Made Owning Chemed Stock In The Last 20 Years

Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) has outperformed the market over the past 5 years by 6.31% on an annualized basis producing an average annual return of 18.79%. Currently, Williams Companies has a market capitalization of $69.22 billion. 
Buying $1000 In WMB: If an investor had bought $1000 of WMB stock 5 years ago, it would be worth $2,371.32 today based on a price of $56.78 for WMB at the time of writing.
<h3>Williams Companies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736452810_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Williams Companies 5 Years Ago Would Be Worth This Much Today

Electric vehicle company BYD Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) is launching the first electric vehicle to come with a starting price under $30,000 in Australia, a move that could boost the country's <a href="https://www.benzinga.com/electric-vehicles">electric vehicle market.</a>
What Happened: Along with investing in blue-chip U.S. companies, Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) CEO Warren Buffett has recognized the investment opportunity<a href="https://www.benzinga.com/news/financing/24/12/42535041/warren-buffett-gains-exposure-to-digital-banks-in-africa-south-america-heres-how"> in emerging markets.</a>
One of Buffett's investments is owning a stake in Chinese company BYD, a global leader in electric vehicle. While Buffett has <a href="https://www.benzinga.com/markets/equities/24/06/39481191/warren-buffets-berkshire-drops-byd-stake-despite-ev-leader-seeing-record-sales">sold a portion</a> of the company's stake in BYD, Berkshire still owns around 4.9% of the company, representing around $1.8 billion in the Berkshire portfolio.
BYD could see a boost to its growth in 2025 thanks to the launch of a new version of its popular Dolphin EV in Australia.
A new stripped-down version of the Dolphin comes with a starting price of $29,900 in Australia, as <a href="https://electrek.co/2025/01/08/byd-just-launched-first-ev-priced-under-30000-australia/">reported </a>by Electrek, <a href="https://www.smh.com.au/politics/federal/chinese-giant-brings-first-ev-for-under-30-000-to-australia-20250108-p5l2vb.html">citing </a>The Sydney Morning Herald.
BYD has launched models like the Dolphin, Atto 3 and Seagull in Australia over the years and it now has the cheapest EV in the country, replacing the previous record of $30,990 by the MG4, which later raised its price to $38,000.
The lower-cost model does not include some normal Dolphin features like a sunroof, heated seats and a wireless phone charger. The new Dolphin model comes with the same battery range of 350 km (217 miles) as the other Dolphin models.
Deliveries of the new Dolphin model are set to begin in March.
You may not be a billionaire like Warren Buffett, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/25/01/42798998/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: BYD is one of the largest electric vehicle companies in the world, selling 4.27 million new energy vehicles globally, which includes electric vehicles and plug-in hybrids, in 2024. This total was up 41% year-over-year.
In Australia, BYD ranked second for 2024 EV sales and had a 14.6% year-over-year gain in units sold. Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) ranked first in 2024 with a market share of 42% of EVs in Australia, but saw its year-over-year sales decline 16.8%, as <a href="https://www.drive.com.au/news/australias-best-selling-electric-cars-2024/">reported </a>by Drive.
Other EV companies like BYD saw their sales gain 28.8% year-over-year while Tesla fell, helping to set a record in Australia for a sixth straight year. The country had 91,292 EVs sold across cars, SUVs and light commercial vehicles, up 4.7% year-over-year and representing 7.4% of all new vehicles sold in the year.
EV sales faced pressure in Australia in the second half of 2024 with an overall drop of 6.9% year-over-year, with Tesla sales falling 25.8% year-over-year and other EV models gaining 9.6% year-over-year.
Tesla had the top two selling vehicles in Australia in 2024 with the Model Y and model 3 ranking first and second respectively.
BYD had three of the top 10 selling EVs in the country with the Seal, Atto 3 and Dolphin ranking fourth, fifth and eighth respectively.
A new lower-priced Dolphin could continue to cut into Tesla's market share. The EV company has watched its market share in Australia fall from 59% in 2022 to 53% in 2023 to 42% in 2024.
The Shark, which is BYD's first pickup truck, has over 5,500 preorders placed according to the report and deliveries begin soon. BYD will also launch the new Sealion 07, which is called a Model Y competitor. The Sealion 07 starts at under $60,000, falling in similar range of the Model Y, which starts at $55,900.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/25/01/42832123/warren-buffett-beats-sp-500-in-2024-how-oracle-of-omahas-returns-compare-over-past-20-years">Warren Buffett Beats S&amp;P 500 In 2024, How Oracle Of Omaha&#8217;s Returns Compare Over Past 20 Years</a></li>
</ul>
BYD photo

Management

BYDDF

BYDDY

TSLA

Warren Buffett-Backed BYD Launches Australia's First EV Under $30K: How The Move Could Strengthen Fight Against Elon Musk's Tesla

Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares dipped 11.2% to $9.60 during Wednesday&#8217;s session, pulling back<a href="https://www.benzinga.com/topic/novavax"> following recent strength. </a>
Shares of vaccine makers are volatile this week after the first bird flu death was reported in the U.S. Additionally, a recent CDC <a href="https://www.cdc.gov/respiratory-viruses/data/index.html#cdc_data_surveillance_section_2-weekly-national-summary">report</a> noted an increase in acute respiratory illness activity.
What To Know: As a company specializing in vaccine development, Novavax is positioned as a potential player in addressing such outbreaks, particularly given its history of <a href="https://www.benzinga.com/general/biotech/24/09/40688052/fda-approves-novavaxs-updated-covid-vaccine-targeting-currently-circulating-variants">creating vaccines</a> for infectious diseases.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/42897161/apples-24-year-70000-climb-since-itunes-faces-2025-test">Apple&#8217;s 24-Year 70,000% Climb Since iTunes Launch Faces 2025 Test</a>
While <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">traditional bird flu vaccines</a> from Sanofi, CSL Seqirus and GlaxoSmithKline are already stockpiled, they target older H5N1 strains, leaving potential room for innovation and updates.
Novavax, with its proprietary recombinant nanoparticle vaccine technology, could be seen as a contender to develop a next-generation bird flu vaccine if demand grows. The bird flu outbreak, which has <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42471357/egg-hyperinflation-could-spike-grocery-prices-why-cal-maine-vital-farms-are-soaring">devastated poultry farms</a> and raised concerns about viral mutations, could also underscore the need for advanced vaccine platforms.
Investor speculation about potential government funding or contracts to combat the outbreak could likely contribute to volatility in Novavax shares, despite the CDC stating that <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">public risk remains low</a>.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies</a>
<h2 class="wp-block-heading">How To Buy NVAX Stock</h2>
By now you're likely curious about how to participate in the market for Novavax &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of Novavax, which is trading at $9.60 as of publishing time, $100 would buy you 10.41 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NVAX has a 52-week high of $23.86 and a 52-week low of $3.53.
Image courtesy of <a href="https://pixabay.com/illustrations/ai-generated-stock-exchange-bull-8477673/">Pixabay</a>

Health Care

NVAX

Why Novavax Stock Is Volatile This Week

James Howells, who is infamously known for having accidentally thrown away a hard drive containing 8,000 Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), has suffered a new setback in his quest to <a href="https://www.benzinga.com/markets/cryptocurrency/22/08/28706518/meet-a-man-on-a-quest-to-find-about-180-million-in-bitcoin-buried-in-a-landfill">reclaim his fortune</a>.
What Happened: A high court ruling by Judge Keyser KC has dismissed James Howells&#8217; legal claim to recover the hard drive, citing no &#8220;reasonable grounds&#8221; for bringing the claim and &#8220;no realistic prospect&#8221; of winning it.
Howells, who had sued the Newport City Council in Wales over the case, said he was &#8220;very upset&#8221; after the ruling, saying &#8220;it&#8217;s the great British injustice system striking again.&#8221;
After trying for 12 years to recover the lost coins, the ruling felt like &#8220;a kick in the teeth,&#8221; Howells lamented.
The case stems from an incident in 2013 when Howells accidentally threw away a hard drive containing 8,000 BTC.
The hard drive was discarded in a landfill in Newport, Wales, and Howells sought permission from Newport Council to <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41308908/man-who-accidentally-threw-hard-drive-containing-8-000-bitcoins-worth-half-a-billion-dolla">excavate the site</a> in order to recover it.
However, the council rejected his request, and the court ruled that the council&#8217;s environmental permits prohibit excavation.
James Goudie KC, representing the council, argued that once the hard drive entered the landfill, it became the council's property.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42881109/bitcoin-is-suffering-from-a-shift-in-macro-expectations-analyst-says-heres-what-that-means">Bitcoin Is Suffering From A Shift In Macro Expectations, Analyst Says: Here&#8217;s What That Means</a>
Why It Matters: At the current market price of $93,128.86, the 8,000 Bitcoins on the discarded hard drive are worth about $745.03 million. 
This is a significant decrease compared to mid-December 2024, when Bitcoin's value peaked at $108,268.45.
Howells had repeatedly requested permission from the council to access the landfill site, offering a share of the Bitcoin in exchange for its recovery. 
Despite his persistent efforts, the court&#8217;s ruling has put an end to his claims.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42900509/social-media-sentiment-report-shows-only-one-out-of-bitcoin-xrp-dogecoin-is-bullish">Social Media Sentiment Report Shows Only One Out Of Bitcoin, XRP, Dogecoin Is Bullish</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Man Who Accidentally Threw Away 8,000 Bitcoin Hard Drive Suffers New 'Kick In The Teeth' As UK Court Dismisses His Claim

Fifth Third Bancorp's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NYSE">FITB</a>) short percent of float has fallen 4.65% since its last report. The company recently reported that it has 18.81 million shares sold short, which is 3.28% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.86 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Fifth Third Bancorp Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736451022_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Fifth Third Bancorp has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Fifth Third Bancorp's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Fifth Third Bancorp's peer group average for short interest as a percentage of float is 0.96%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

FITB

Looking Into Fifth Third Bancorp's Recent Short Interest

Tonix Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NYSE">TNXP</a>) short percent of float has risen 151.76% since its last report. The company recently reported that it has 4.00 million shares sold short, which is 2.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tonix Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736451017_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tonix Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tonix Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tonix Pharmaceuticals's peer group average for short interest as a percentage of float is 4.81%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

TNXP

(TNXP) - Analyzing Tonix Pharmaceuticals's Short Interest

JPMorgan Chase's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) short percent of float has fallen 4.59% since its last report. The company recently reported that it has 29.19 million shares sold short, which is 1.04% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.86 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>JPMorgan Chase Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736451012_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for JPMorgan Chase has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing JPMorgan Chase's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, JPMorgan Chase's peer group average for short interest as a percentage of float is 1.06%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(JPM) - Analyzing JPMorgan Chase's Short Interest

In the current market session, Select Medical Hldgs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) share price is at $18.73, after a 0.48% increase. Moreover, over the past month, the stock decreased by 5.59%, but in the past year, spiked by 31.69%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1736450112_0.png" alt="Past Year Chart" />

<h3>Select Medical Hldgs P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 25.68 in the Health Care Providers &amp; Services industry, Select Medical Hldgs Inc. has a lower P/E ratio of 8.75. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1736450112_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

Price Over Earnings Overview: Select Medical Hldgs

<a href="https://www.ft.com/content/38c519c3-1fe9-4d2c-9d8c-6dd158ab35aa" title="https://www.ft.com/content/38c519c3-1fe9-4d2c-9d8c-6dd158ab35aa">https://www.ft.com/content/38c519c3-1fe9-4d2c-9d8c-6dd158ab35aa</a>

Politics

General

OKLO

Report From Jan. 3 "US relaxes green hydrogen rules in race to boost sector" -Financial Times

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping <a target="_blank" href="https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more" rel="noreferrer noopener">investor outlook for 2025</a>.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector&#8217;s performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500&#8217;s 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Ahead of the 2025 JPM Healthcare Conference, JP Morgan highlights some investor expectations as sentiment remains mixed for the US Large Cap BioPharma group heading into 2025. The conference is scheduled between 13 January and 16 January.
Obesity is expected to remain a major focus for the industry. The sector&#8217;s focus on the below advancements highlights the growing importance of obesity treatments and related drug innovations:
<ul>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>): Increased emphasis on incretin therapies as production capacity grows and direct-to-consumer advertising gains traction. Key data catalysts: Phase 3 results for orforglipron, an oral <a href="https://www.benzinga.com/general/biotech/23/07/33339766/ozempic-alternatives-these-two-drugs-show-promise-in-affordability-and-effectiveness-for-weight-l" target="_blank" rel="noreferrer noopener">small molecule GLP-1</a>.</li>
<li>Initial outcomes data for tirzepatide <a href="https://www.benzinga.com/general/biotech/24/08/40460727/eli-lillys-famed-obesitydiabetes-treatment-tirzepatide-shows-potential-to-cut-risk-of-developing-" target="_blank" rel="noreferrer noopener">in type 2 diabetes</a>.</li>
</ul>
Several new product launches are on the radar for 2025. Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) stands out as a top pick, with the anticipated launch of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea" rel="noreferrer noopener">Cobenfy for schizophrenia</a>.
JP Morgan analyst Chris Schott expects a strong adoption once broader insurance coverage, expected by the second half of 2025, is in place.
Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is also preparing for a mid-2025 launch of lenacapavir for pre-exposure prophylaxis, with promising uptake <a target="_blank" href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" rel="noreferrer noopener">projected into 2026</a>.
Additionally, JP Morgan is monitoring Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Winrevair for pulmonary arterial hypertension, which has already <a target="_blank" href="https://www.benzinga.com/25/01/42768614/uk-approves-mercks-hypertension-drug-acquired-via-11-billion-acceleron-pharma-deal" rel="noreferrer noopener">exceeded early expectations</a>, and Gilead&#8217;s Livdelzi for primary biliary cholangitis, expected to see more significant growth in 2025 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42016935/gilead-unveils-long-term-data-from-seladelpar-in-patients-with-rare-liver-disease" rel="noreferrer noopener">as access improves</a>.
The analyst is watching for updates on how companies are approaching business development after a relatively quiet 2024. While major changes are not anticipated in the size or type of deals pursued by large-cap companies, JP Morgan expects M&amp;A activity to pick up in 2025.
Large deals over $25 billion remain unlikely, with mid-sized deals around $5-15 billion likely to focus on later-stage, lower-risk assets.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42898400/sanofis-blood-cancer-drugs-new-subcutaneous-formulation-hits-primary-goal-in-late-stage-in-multiple-myeloma" target="_blank" rel="noreferrer noopener">Sanofi&#8217;s Blood Cancer Drug&#8217;s New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma</a></li>
</ul>
Image via Shutterstock

Analyst Color

Biotech

Large Cap

Analyst Ratings

AMGN

GILD

REGN

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference

Marvell Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) shares are trading higher by some 7% to $118.23 over the trailing week. JPMorgan analyst Harlan Sur this week <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42859614/jpmorgan-sees-marvells-ai-revenue-surge-with-2-billion-run-rate-in-networking-by-2025">provided an optimistic outlook</a> for the company, highlighting the company's strong momentum in AI-driven growth.
Marvell also unveiled its <a href="https://www.benzinga.com/news/25/01/42820909/whats-going-on-with-marvell-technology-mrvl-stock">custom XPU architecture</a>, integrating co-packaged optics to enhance AI server scalability with superior data transmission reach and energy efficiency.
What To Know: Sur <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42859614/jpmorgan-sees-marvells-ai-revenue-surge-with-2-billion-run-rate-in-networking-by-2025">highlighted</a> that Marvell is set to surpass its $2.5 billion AI revenue target for CY25, fueled by robust demand for optical and copper networking products and AI ASIC programs with Amazon and Google.
Read Also: <a href="https://www.benzinga.com/25/01/42899028/la-wildfire-damages-estimated-above-52-billion-california-property-insurance-crisis">LA Wildfire Damages Could Top $52 Billion As California Faces Property Insurance Crisis</a>
The company is also expanding into scale-up networking with advanced solutions like active electrical cables, co-packaged optics and linear pluggable optics.
Sur noted Marvell's partnership with Amazon remained solid, with expectations of sustained multi-generational product wins. Despite competition from Amazon's 3nm AI compute ASIC program, Marvell anticipated no revenue disruptions through CY26, projecting continued growth.
Sur also described the company's $8 billion AI Custom ASIC revenue target for CY28 as conservative given the market's rapid expansion.
Read Also: <a href="https://www.benzinga.com/general/market-summary/25/01/42895251/mrvl-stock-has-gained-over-7-in-last-five-sessions-as-marvell-technologys-new-chip-boosts-ai-server-performance-heres-what-technical-analysis-says">MRVL Stock Has Gained Over 7% In Last Five Sessions As Marvell Technology&#8217;s New Chip Boosts AI Server Performance: Here&#8217;s What Technical Analysis Says</a>
<h1 class="wp-block-heading">Is MRVL A Good Stock To Buy?</h1>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages — such as <a href="https://www.benzinga.com/quote/MRVL">Marvell</a>&#8216;s page for example — there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Marvell Tech does pay a dividend, which yields 0.31% per year as of the closing price on Jan. 9, 2025. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 18.34%, you'll need to buy a share of Orchid Island Cap by Jan. 31, 2025. Once done, you can expect to receive a nominal payout of $0.12 on Feb. 12, 2025.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/MRVL">Marvell</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, MRVL has a 52-week high of $126.12 and a 52-week low of $53.19.
Image courtesy of <a href="http://Pixabay">Pixabay</a>

Movers

MRVL

What's Going On With Marvell Technology (MRVL) Stock?

As Washington ramps up chip export restrictions to unfriendly countries, Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) are in the midst of a geopolitical power shift that could disrupt the semiconductor <a href="https://www.benzinga.com/topic/semiconductors">industry&#8217;s global landscape.</a>
In a report shared Monday, Bloomberg outlined the Biden administration&#8217;s imminent release of updated export <a href="https://www.benzinga.com/government/regulations/25/01/42897081/nvidia-and-ai-chip-stocks-brace-for-impact-as-biden-administration-considers-new-china-export-ban-report">rules targeting advanced semiconductors. </a>
The new measures, expected to drop Friday, intensify the U.S.&#8217;s strategic efforts to slow China's technological and military advancements by restricting access to high-performance computing chips.
<h3 class="wp-block-heading">New AI Export Framework: Allies And Adversaries</h3>
The regulations will reportedly create a three-tiered structure for semiconductor exports, emphasizing access tiers for key U.S. allies, neutral nations, and restricted countries. 
China is expected to fall under the most severe tier, joining nations such as Russia, Iran, and Venezuela.
This tier-based framework allows certain companies in restricted countries to bypass national limits by agreeing to U.S. security protocols and human rights standards. 
These entities, designated as validated end users, would have higher caps for chip purchases, a move aimed at encouraging safer AI development globally.
The measures expand the sweeping export restrictions initiated in October 2022, which already limited sales of advanced AI chips like Nvidia's Hopper GPUs. 
These earlier rules also prohibited U.S. firms and individuals from supporting Chinese chip development without explicit government approval. 
<h3 class="wp-block-heading">Nvidia And AMD Under Scrutiny</h3>
Nvidia's specialized A800 and H800 chips, developed to comply with prior regulations, could now fall under new restrictions, potentially denting AI giant&#8217;s upcoming revenues. 
According to data firm FactSet, China accounts for approximately 16% of Nvidia&#8217;s revenue, making it the company's second-largest market after the U.S. This marks a decline from 25% prior to the 2022 export restrictions.
In 2023, AMD generated roughly $3.4 billion in revenue from China, including Hong Kong, according to Statista. This represents 15% of the company&#8217;s total revenue of $22.7 billion.
<h3 class="wp-block-heading">Key ETFs Tied To Nvidia And AMD</h3>
Several ETFs heavily exposed to Nvidia and AMD could face ripple effects:
Top ETFs Holding Nvidia (Percentage of Holdings):
<ul>
<li>ProShares Ultra Semiconductors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USD#NYSE">USD</a>): 34.96%</li>
<li>Strive U.S. Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOC#NASDAQ">SHOC</a>): 21.10%</li>
<li>YieldMax Target 12 Semiconductor Option (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXY#NASDAQ">SOXY</a>): 20.50%</li>
<li>VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>): 20.21%</li>
<li>VanEck Fabless Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMHX#NASDAQ">SMHX</a>) – 20.11%</li>
</ul>
Top ETFs Holding AMD (Percentage of Holdings):
<ul>
<li>VanEck Video Gaming and Esports ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPO#NASDAQ">ESPO</a>): 8.01%</li>
<li>iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>): 7.12%</li>
<li>AOT Growth and Innovation ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOTG#NASDAQ">AOTG</a>): 7.07%</li>
<li>Invesco PHLX Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXQ#NASDAQ">SOXQ</a>): 7.04%</li>
<li>REX FANG &amp; Innovation Equity ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEPI#NASDAQ">FEPI</a>): 6.95%</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42888800/goldman-sachs-flags-market-correction-risk-as-inflation-trump-policies-stir-uncertainty">Goldman Sachs Flags Market Correction Risk As Inflation, Trump Policies Stir Uncertainty</a></li>
</ul>
Image created using photos from Shutterstock.

Asia

Government

Regulations

Sector ETFs

Global

ETFs

AOTG

ESPO

FEPI

NVDA

EA Series Trust Strive U.S. Semiconductor ETF

SHOC

SMHX

SOXQ

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

SOXY

Biden's Final Chip Curbs Set To Shake AI Markets: 10 ETFs With High Stakes In Nvidia, AMD

<a target="_blank" href="https://www.benzinga.com/topic/airlines" rel="noreferrer noopener">Earlier this week</a> at CES 2025, Delta Air Lines, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) demonstrated Delta Concierge, an AI-powered digital tool that will add advanced capabilities to its Fly Delta app <a target="_blank" href="https://news.delta.com/delta-unveils-ai-powered-travel-journey-new-multi-modal-transportation-options" rel="noreferrer noopener">beginning in 2025</a>.
The airline also announced &#8216;multi-modal&#8217; transportation options offered through Delta partners Uber Technologies, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and Joby Aviation, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>).&nbsp;
The airline added Delta Concierge to the Fly Delta app for a seamless, personalized travel experience that leverages generative AI.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42872581/microns-7-billion-bet-on-ai-driven-memory-singapore-facility-set-to-boost-innovation-and-jobs" rel="noreferrer noopener">Micron&#8217;s $7 Billion Bet on AI-Driven Memory In Singapore Facility Set to Boost Innovation</a>
At CES in 2020, Delta previewed its &#8216;concierge&#8217; concept. Delta also previewed new partnerships with&nbsp;Uber and&nbsp;Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) YouTube, including its expectations from its&nbsp;Joby partnership.&nbsp;
Delta is striving to build customer loyalty using data and AI. The AI assistant will work to create time-saving efficiencies, including notifying customers about passport expiration, visa requirements, weather updates, and wayfinding at unfamiliar airports.
In the future, Delta Concierge will enable customers to automatically connect to Delta Sync Wi-Fi and Delta Sync seatback, the airline&#8217;s personalized in-flight entertainment experience.
Delta also outlined a multimodal future of travel in which a single customer itinerary will be connected from start to finish through deep partner integrations. The Delta-Uber partnership will allow customers to earn miles for eligible rides and deliveries.
Delta Concierge will also connect with Joby&#8217;s&nbsp;electric air taxi&nbsp;service. Delta and Joby announced their alliance in 2022 and expect to begin operating in Delta&#8217;s New York and Los Angeles hubs.
B Of A Securities&#8217; Andrew G. Didora <a target="_blank" href="https://www.benzinga.com/25/01/42824930/bofa-expects-deltato-maintain-10-eps-growth-in-2025-sees-strong-q4-result" rel="noreferrer noopener">raised estimates for</a> Delta ahead of its fourth-quarter print. Didora raised the quarterly revenue growth estimate to 4.3% (prior 3.6%), versus the 2%-4% outlook. He expects EPS of $1.78 versus the guidance of $1.60-$1.85.
Morgan Stanley&#8217;s Ravi Shankar maintained&nbsp;<a target="_blank" href="https://www.benzinga.com/general/travel/24/12/42450095/us-airlines-set-to-fly-high-in-2025-analyst-says-perfect-storm-of-tailwinds-will-propel-industry-gains" rel="noreferrer noopener">a bullish outlook</a> on the airline industry. The analyst flagged how airlines like Delta reaped the benefits of &#8220;the premiumization trend,&#8221; backed by loyalty programs, credit cards, and brand partnerships. Goldman Sachs&#8217; Catherine O&#8217;Brien <a target="_blank" href="https://www.benzinga.com/24/11/42119662/goldman-sachs-analyst-sees-delta-eps-soaring-to-950-by-fy26-details" rel="noreferrer noopener">also voiced similar</a> sentiments.
Delta chief Ed Bastian&nbsp;had signaled <a target="_blank" href="https://www.benzinga.com/news/global/24/11/42106369/delta-chief-says-trump-could-be-a-breath-of-fresh-air-for-aviation-industry" rel="noreferrer noopener">positive regulatory changes</a> for the industry under Donald Trump&#8217;s presidency.
Delta stock surged over 45% in the last 12 months. Investors can gain exposure to the stock through U.S. Global Jets ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JETS#NYSE">JETS</a>) and iShares U.S. Financial ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYF#NYSE">IYF</a>).
Price Action: DAL stock closed at $61.18 on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/42871786/acuity-brands-earnings-beats-profit-estimates-smart-spaces-revenue-soars-145-expands-into-cloud-tech-with-12-billion-deal" target="_blank" rel="noreferrer noopener">Acuity Brands Q1 Earnings: Revenue Miss, Smart Spaces Revenue Soars 14.5%, Expands Into Cloud Tech With $1.2 Billion Deal</a></li>
</ul>
Photo by VanderWolf via Shutterstock

GOOG

GOOGL

iShares Dow Jones US Financial Sector Index Fund

JETS

JOBY

UBER

Delta Expands Premium Travel Experience with Uber, YouTube, and Joby Partnerships

President Jimmy Carter's solemn <a href="https://www.benzinga.com/movers-shakers/24/12/42716329/jimmy-carter-the-39th-us-president-who-championed-human-rights-and-peace-in-the-middle-east-had-died">state funeral</a> in Washington, D.C.&#8217;s National Cathedral Thursday brought together five living U.S. presidents, including President-elect Donald Trump, who was seated next to Barack Obama, with whom he seemed to be having a lively conversation. &nbsp;
Carter was <a href="https://www.benzinga.com/topic/jimmy-carter">president from 1977 to 1981.</a>
The first eulogy was given by one of Carter's grandsons, Joshua Carter, who said his grandfather spent his life helping people and seeking peace and justice around the world. He was followed by eulogies written by former President Gerald Ford and Walter Mondale, Carter&#8217;s vice president, before their deaths and read by the sons.
<h1 class="wp-block-heading">&#8220;The First Millennialist&#8221;</h1>
Jason Carter called his grandfather the first millennialist who wanted to legalize cannabis, encouraged craft beer production, protected the environment, supported women's rights and "tried to bring peace to the Holyland."
He drew laughs when he told an endearing story about how his grandfather, a nuclear engineer, first began using a cell phone and called him: &#8220;I answered and said &#8216;Hey paw paw.&#8217; He said &#8216;Who&#8217;s this.&#8217; I said this is Jason, you called me.&#8221; 
Carter replied, &#8220;I didn&#8217;t call you, I&#8217;m taking a picture.&#8221;
<h2 class="wp-block-heading">President Joe Biden</h2>
In his eulogy, President Joe Biden summed up Carter's character in three words "Character, character, character." He called Carter a white Southerner who championed civil rights and established a model post-presidency.
"He showed us how character and faith start with ourselves and then flows to others. At our best, we share the better parts of ourselves — joy, solidarity, love, commitment — not for reward, but in reverence of the incredible gift of life we've all been granted, to make every minute of our time here on Earth count," Biden said. 
&#8220;We have an obligation to give hate no safe harbor and we have to stand up to what my dad used to say was the greatest sin of all — the abuse of power." At this point the cameras turned to the section of the audience where Trump was seated.
As the presidents made their way to the exit of the Cathedral, Trump, Obama and Bush went one way and Clinton another, <a href="https://www.nytimes.com/live/2025/us/jimmy-carter-funeral">noted</a> the NY Times. Doug Emhoff, Vice President Kamala Harris's husband shook Trump&#8217;s hand, which Bush did not, <a href="https://www.newsbreak.com/raw-story-2096750/3752745200176-watch-george-w-bush-declines-to-shake-donald-trump-s-hand-at-jimmy-carter-s-funeral">noted</a> CBS anchor Norah O&#8217;Donnell.
<h1 class="wp-block-heading">Final Resting Place</h1>
Following the service, Carter was taken to the Joint Base Andrews outside of Washington, D.C., to be flown on one of Air Force One jets to Georgia where there will be a final private service Thursday afternoon at Carter&#8217;s local church. Carter will be buried next to his wife, <a href="https://www.benzinga.com/top-stories/23/11/35865944/former-first-lady-and-mental-health-champion-rosalynn-carter-dies-at-96">Rosalynn Carter</a>, outside the home they built in 1961 and where they lived most of their lives.
&#8220;Yes, they spent four years in the governor's mansion and four years at the White House but the other 92 years they spent at home in Plains, Georgia, which first of all looks like they built themselves," said grandson Jason Carter.
"Second of all, my grandfather was likely to show up at the door in some &#8217;70s short shorts and crocs. Demonstrating their depression, era roots, they had a little rack next to the sink where they would hang Ziploc bags to dry."
Photo: Jimmy Carter in 1977; Photo by Bernard Gotfyd via Library of Congress

Cannabis

Jimmy Carter's Funeral: 5 Living Presidents Attend; Family, Colleagues Share Warm, Humorous Stories

Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) disclosed the commencement of oil production from the Whale semi-submersible platform in the<a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42899245/chevron-bolsters-u-s-gulf-of-mexico-production-with-whale-facility-startup" rel="noreferrer noopener"> deepwater U.S. Gulf of Mexico</a>.
The company&#8217;s subsidiary, Chevron U.S.A. Inc., owns 40% working interest in Whale, with Shell Offshore Inc. owning 60% interest as operator.
Whale, located 200 miles southwest of Houston in Alaminos Canyon Block 773, is in over 8,600 feet of water.
The company estimates Whale&#8217;s peak production at 100,000 gross boe/d, with up to 15 wells in its first phase.
The project features energy-efficient gas turbines and compression systems, utilizing a simplified design for lower emissions, reduced costs, and higher returns.
Chevron&#8217;s latest milestone follows a year of key achievements, including first production from its high-pressure Anchor project and the launch of water injection operations to enhance output at its Jack/St. Malo and Tahiti facilities in the Gulf.
Bruce Niemeyer, president of Chevron Americas Exploration &amp; Production, stated Whale&#8217;s production brings Chevron nearer to its target of 300,000 net barrels of oil equivalent per day in the U.S. Gulf of Mexico by 2026.
Last month, Chevron and Woodside swapped energy assets, with Chevron gaining Julimar-Brunello stakes and <a target="_blank" href="https://www.benzinga.com/news/contracts/24/12/42584936/chevron-secures-larger-north-west-shelf-stake-in-asset-swap-400m-payment-to-woodside" rel="noreferrer noopener">Woodside focusing on LNG assets</a>.
Investors can gain exposure to the stock via EA Series Trust Strive U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRLL#NYSE">DRLL</a>) and SPDR Select Sector Fund &#8211; Energy Select Sector (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>).
Price Action: CVX shares closed higher by 0.47% at $150.30 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42883117/in-an-unpredictable-market-here-are-some-potential-winners-and-losers-for-the-first-quarter" target="_blank" rel="noreferrer noopener">In an Unpredictable Market Here Are Some Potential Winners and Losers for the First Quarter</a></li>
</ul>
Image via Shutterstock.

Equities

DRLL

Chevron Kicks Off Whale Oil Production: Details

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Invesco Health Care Fund Q3 2024 Commentary

Catalyst Watch: November jobs, OPEC+ meeting, Marvell, Salesforce earnings

Salesforce, Marvell Technology, And Kroger Report As Earnings Season Slowing To A Crawl

Phathom Pharmaceuticals (PHAT) announced it has submitted a Citizen Petition, CP, with the U.S. Food and Drug Administration, FDA. The petition for...

Phathom Pharmaceuticals submits Citizen Petition to FDA

Needham analyst Joseph Stringer maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) today and set a price target of $28.00....

Phathom Pharmaceuticals: Undervalued Opportunity with Strategic Moves for Extended Exclusivity

Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report), with...

Phathom Pharmaceuticals: Securing Long-term Exclusivity for Growth Potential

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report). The ...

Craig-Hallum Remains a Buy on Phathom Pharmaceuticals (PHAT)

Investing in biotechnology stocks offers a unique opportunity for individuals looking to gain exposure to one of the most dynamic and innovative sectors of the market.

Comments

Phathom Pharmaceuticals

Notizie

Ultime notizie per Phathom Pharmaceuticals (NASDAQ:PHAT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO